Program
teprotumumab
Also written as “Teprotumumab”, “RG1507” and “TEPEZZA”.
Its studies are mostly in Graves Ophthalmopathy · Neoplasms · Macular Edema · Scleroderma, Diffuse · Sarcoma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 121 open or running | phase 4since Oct 6, 2020 | May 2, 2013 | none ahead |
| Hoffmann-La Roche | 60 open or running | phase 2since Mar 19, 2008 | Nov 15, 2006 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Nov 15, 2006.
- Dec 18, 2008Phase 1 study in NeoplasmsHoffmann-La Roche · NCT00811993 · 104 enrolled · United States
- Apr 15, 2009Phase 1 study in Breast NeoplasmsHoffmann-La Roche · NCT00882674 · 8 enrolled · United Kingdom
- May 2, 2013Amgen's first study: phase 2 study in Graves OphthalmopathyNew to AmgenAmgen · NCT01868997 · 88 enrolled · United States, Germany, Italy and more
- Mar 27, 2014Phase 1 study in Diabetic Macular EdemaAmgen · NCT02103283 · 5 enrolled · United States
- Sep 27, 2017Phase 3 study in Graves OphthalmopathyAmgen · NCT03298867 · 83 enrolled · United States, Germany, Italy
- Mar 5, 2018Phase 3 study in Graves OphthalmopathyAmgen · NCT03461211 · 51 enrolled · United States, Germany, Italy
- Jul 16, 2020Phase 1 study in Scleroderma, DiffuseAmgen · NCT04478994 · 3 enrolled · United States
- Oct 6, 2020Phase 4 study in Graves OphthalmopathyAmgen · NCT04583735 · 62 enrolled · United States
- Jul 19, 2021Phase 4 study in Graves OphthalmopathyAmgen · NCT05002998 · 313 enrolled · United States, France, Germany and more
- Jan 31, 2024Phase 3 study in Graves OphthalmopathyAmgen · NCT06248619 · 89 enrolled · United States, Argentina, Australia and more
- Apr 24, 2024Phase 1 study in Graves OphthalmopathyAmgen · NCT06389578 · 16 enrolled · United States
- Aug 19, 2024Phase 1 study in Graves OphthalmopathyAmgen · NCT06563856 · 37 enrolled · United States
- Nov 4, 2024Phase 1 study in Graves OphthalmopathyAmgen · NCT06674941 · 44 enrolled · United States
- Aug 25, 2025Phase 1 study in Graves OphthalmopathyAmgen · NCT07142642 · 20 enrolled · China
TargetBeta
“A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor-1 receptor (IGF-1R) ”NCIt, by rule
“Insulin-like growth factor I receptor antagonist”ChEMBL 37, by rule
Other programs on IGF1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| veligrotugrule | viridian-therapeutics-inc | phase 4 | 7 |
| linsitinibrule | Astellas Pharma | phase 3 | 13 |
| MHB018Arule | Minghui Pharmaceutical | phase 3 | 6 |
| IBI311rule | Innovent Biologics | phase 3 | 5 |
| IBI3031rule | Innovent Biologics | phase 1 | 1 |
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07142642Graves Ophthalmopathy · China | 1 | Completed | Amgen | Nov 22, 2025 | 20 |
| NCT06674941Graves Ophthalmopathy · United States | 1 | Completed | Amgen | Nov 14, 2023 | 44 |
| NCT06563856Graves Ophthalmopathy · United States | 1 | Completed | Amgen | May 27, 2021 | 37 |
| NCT06389578Graves Ophthalmopathy · United States | 1 | Completed | Amgen | Feb 28, 2023 | 16 |
| NCT06248619Graves Ophthalmopathy · United States, Argentina, Australia and more | 3 | Active, not recruiting | Amgen | Dec 23, 2025 | 89 |
| NCT05002998Graves Ophthalmopathy · United States, France, Germany and more | 4 | Completed | Amgen | Dec 19, 2025 | 313 |
| NCT04583735Graves Ophthalmopathy · United States | 4 | Completed | Amgen | Mar 17, 2023 | 62 |
| NCT04478994Scleroderma, Diffuse · United States | 1 | Terminated | Amgen | Nov 29, 2022 | 3 |
| NCT03461211Graves Ophthalmopathy · United States, Germany, Italy | 3 | Completed | Amgen | Jun 8, 2020 | 51 |
| NCT03298867Graves Ophthalmopathy · United States, Germany, Italy | 3 | Completed | Amgen | Feb 13, 2019 | 83 |
| NCT02103283Diabetic Macular Edema · United States | 1 | Completed | Amgen | Aug 2016 | 5 |
| NCT01868997Graves Ophthalmopathy · United States, Germany, Italy and more | 2 | Completed | Amgen | Mar 2016 | 88 |
| NCT00882674Breast Neoplasms · United Kingdom | 1 | Completed | Hoffmann-La Roche | Dec 2010 | 8 |
| NCT00811993Neoplasms · United States | 1 | Terminated | Hoffmann-La Roche | Dec 2012 | 104 |
| NCT00773383Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more | 2 | Terminated | Hoffmann-La Roche | Feb 2010 | 35 |
| NCT00642941Sarcoma · United States, Australia, Canada and more | 2 | Terminated | Hoffmann-La Roche | Feb 19, 2014 | 317 |
| NCT00560144Neoplasms · United States | 1 | Completed | Hoffmann-La Roche | Dec 2011 | 34 |
| NCT00400361Neoplasms · United States | 1 | Completed | Hoffmann-La Roche | Apr 2011 | 98 |
How it is read
Names in the registry
- “Teprotumumab”, 8 entries
- “RG1507”, 8 entries
- “TEPEZZA”, 3 entries
- “teprotumumab”, 1 entry
Conditions, from the studies’ own filings
- Graves Ophthalmopathy, 10 studies
- Neoplasms, 3 studies
- Macular Edema, 1 study
- Scleroderma, Diffuse, 1 study
- Sarcoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.